Sagimet's denifanstat shows sustained acne efficacy at 52 weeks
Sagimet Biosciences has announced it will present 52-week data from the Phase 3 open-label extension of denifanstat in moderate to severe acne vulgaris at the 2026 Fall Clinical Dermatology Conference in Las Vegas. The results, generated by Chinese licence partner Ascletis BioScience under the trial designation ASC40-304, were characterised by the company as positive across all efficacy endpoints.
The extension trial enrolled 240 patients who had completed the earlier 12-week, double-blind, placebo-controlled Phase 3 study ASC40-303. At 52 weeks, patients treated with denifanstat showed a 57% rate of Investigator's Global Assessment success, a 72% reduction in total lesion count and a 77% reduction in inflammatory lesions from baseline. The drug was reported as generally well-tolerated, though detailed safety data, including discontinuation rates and adverse event profiles, were not released in the announcement.
The poster presentation will be delivered by dermatologist Julie Harper, founding director and past president of the American Acne and Rosacea Society, and will include preclinical mechanistic evidence alongside the clinical data.
The science behind FASN inhibition
Denifanstat is a once-daily oral small molecule that blocks fatty acid synthase, an enzyme central to lipid synthesis. The mechanistic rationale for using a FASN inhibitor in acne rests on the drug's ability to reduce de novo lipogenesis in sebaceous glands, thereby cutting sebum production and downstream inflammation. Both pathways are considered core drivers of acne pathogenesis, and the approach is positioned as novel relative to current standard-of-care options such as topical retinoids, antibiotics and isotretinoin.
Ascletis submitted a new drug application to China's National Medical Products Administration in December 2025; that submission was accepted for review, making an approval decision in China the nearest-term regulatory milestone for the programme.
AURORA and the US opportunity
Sagimet is separately running its own Phase 3 trial, AURORA, in the United States. The study is designed to enrol approximately 800 patients aged 12 and over, with around 530 of the adolescent and adult completers eligible to enter a 40-week open-label safety extension. Sites have received IRB approval and patient screening began in October 2026. The trial carries three co-primary endpoints at week 12, covering global assessment success, inflammatory lesion count and non-inflammatory lesion count.
The acne market remains significant. Around 50 million Americans are affected annually, and the moderate to severe segment that denifanstat targets represents an estimated 10 million patients. Current oral systemic options carry meaningful safety caveats, particularly for adolescent populations: isotretinoin requires risk-management programme enrolment and is associated with teratogenicity, and long-term antibiotic use raises stewardship concerns. An oral, non-antibiotic, non-retinoid option with a well-characterised safety profile would address a genuine gap, provided the AURORA data replicate the Ascletis findings across a predominantly Western patient population.
The competitive field is not empty. Several companies are developing topical pipeline candidates, and at least one biologics approach targeting the interleukin pathway has been explored in acne. However, a well-tolerated oral small molecule with 52-week durability data would be a differentiated offering if the US trial confirms the Chinese programme's efficacy signal.
Chief executive David Happel said denifanstat had "demonstrated significant and sustained improvements in moderate to severe acne through 52 weeks of treatment" and cited the activation of AURORA sites as evidence of near-term momentum.
Investors will want to see Sagimet translate the favourable Ascletis dataset into a positive US readout, particularly given that Phase 3 results in Chinese patient populations do not always generalise directly to global regulatory filings.